Marshall Wace, LLP Alnylam Pharmaceuticals, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 378,649 shares of ALNY stock, worth $100 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
378,649
Previous 63,467
496.61%
Holding current value
$100 Million
Previous $17.5 Million
410.36%
% of portfolio
0.11%
Previous 0.02%
Shares
11 transactions
Others Institutions Holding ALNY
# of Institutions
686Shares Held
110MCall Options Held
1.23MPut Options Held
1.19M-
Capital World Investors Los Angeles, CA16.6MShares$4.4 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.37 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.53 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.97MShares$1.85 Billion0.35% of portfolio
-
Wellington Management Group LLP Boston, MA4.2MShares$1.11 Billion0.19% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $32.6B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...